Kelsy Ketchum

Findings from two clinical studies were reported at Digestive Disease Week earlier this month that supported use of the firm's EsoCheck device and EsoGuard test.

The Oregon Health and Science University spinout also recently presented data suggesting the test could help predict future urothelial carcinoma. 

The firm's platform combines single-cell microbiology and machine learning to deliver a result in four to six hours. 

The firm's non-respiratory revenue was up 5 percent due to the Labs business, while respiratory revenue was down 72 percent.

Diagnostics and Genomics segment revenues ticked down 3 percent year over year, while Protein Sciences revenues were up 3 percent.

The company's point-of-care revenues dropped 73 percent, while molecular lab sales declined 50 percent.

The firm saw total revenues decrease 7 percent, with core revenues down 4 percent and base business core revenue growth of 6 percent.

The firm's Lodestar Dx platform uses loop-mediated isothermal amplification to detect pathogens causing urinary tract infections.

The firm's planned launches include a respiratory virus panel, a gastrointestinal panel, and a fingerstick tuberculosis test, it revelaed this week at ECCMID.

The assay received de novo authorization from the US Food and Drug Administration and CE-IVD marking last year.